Solentim launches new workflow for single cell cloning of stem cells

VIPS™ + MatriClone™ combination ensures high efficiency seeding of hiPSCs with high viability

Bournemouth, UK, 23rd September 2020 / Sciad Newswire / Solentim, the global leader for solutions to create, isolate and characterize the highest value cells for the development of new biological medicines, yesterday launched a dedicated new workflow for single cell cloning of human induced pluripotent stem cells (hiPSCs). A combination of Solentim’s VIPS™ (verified in-situ plate seeding) instrument and the new MatriClone™ matrix has been shown to give a 4 to 5-fold improvement in cloning efficiency compared with traditional limiting dilution methods (see new application note). 

Over the last three years, Solentim’s VIPS has become an industry standard for single cell cloning of CHO and HEK manufacturing cell lines in combination with the company’s InstiGRO™ growth supplements. Now, the VIPS repertoire has been extended to include hiPSC cells to address the industry challenges of poor clone viability after single cell seeding, a lack of standardization for assurance between labs and for documentation of clonality. For further information watch our latest webinar.

The VIPS can deliver around 80% seeding efficiency and allows for high viability and outgrowth of stem cell colonies due to the gentle seeding method in combination with MatriClone, an animal component-free matrix used in solution at the time of seeding. The VIPS is then able to track the single cell origin and progression to a colony using daily whole well imaging and provide a Clonality Report which can be supplied to a regulator as part of an IND submission.

Mark Truesdale, CEO, Solentim, commented: “The combination of the VIPS and MatriClone soluble matrix is a significant workflow improvement for customers doing cell reprogramming or gene editing of iPSCs. We are delighted to be able support the fast-growing use of stem cells in both research, such as disease models, as well as in the advancement of stem cell therapies, such as the very exciting field of allogeneic cell therapy.” Dr Truesdale added, “our existing Cell Metric^® customers can also purchase MatriClone and immediately begin to demonstrate the benefits for their existing iPSC projects.”

Solentim is also working to support customers in future manufacturing by implementing a GAMP-5 policy. Dr Truesdale commented, “We have always placed quality as a central pillar in our work. With our new GAMP-5 policy, we look to further integrate with our customer’s GMP requirements as they move towards the development of stem cell therapies.”

ENDS

For further information, contact:

Solentim Ltd
Dr Mark Truesdale, CEO
T: +44 (0)1202 798510           
E: mark.truesdale@solentim.com 

Media Relations – Sciad Communications
Emma Pickup 
T: +44 (0)20 3405 7892
E: solentim@sciad.com

Notes to editors 

About Solentim
Solentim is the trusted global leader for solutions to create, isolate, and characterize the highest value cells for the development of new biological medicines, including cell and gene therapies, monoclonal antibodies, vaccines and stem cells. For our customers, which include most of the world’s leading pharmaceutical and biotherapeutics companies, we are the partner of choice for facilitating the highest level of assurance in cell line development for therapeutic protein and viral vector production. 

Our portfolio of proven and innovative instruments (including VIPS™, Cell Metric^® and Cell Metric^® CLD) are designed for single cell cloning and assurance of monoclonality. Combined with enabling reagents (including InstiGRO™ and Leap-In Transposase^®) from our partners, and our unparalleled domain expertise, we transform the speed and efficiency of clonally derived Master Cell Bank development. Our customers trust in our technology to ensure they are confidently prepared for regulatory review.